Outcome analysis of liraglutide versus other antidiabetic medications in type 2 diabetes

• At: Glasgow (Scotland) (2018)
• Type: Poster
• Poster code: POS-HPS-015
• By: CHANG, Hsiu-Mei (Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Department of Pharmacy)
• Co-author(s): Hsiu-Mei Chang: Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  Jiun-Shiuan He: Department of Management, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  Kun-Der Lin: Division of Endocrinology & Metabolism, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  Yen-Huei (Tony) Tarn: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  Ying-Chi Lin: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  
• Abstract:

  Background

  Liraglutide is a glucagon-like peptide-1(GLP-1) receptor agonist approved for the treatment of type-2 diabetes mellitus (T2DM). Despite of high cost, liraglutide gradually become popular in our hospital since its availability in 2012.

  Methods

  A retrospective cohort study in adult patients diagnosed with T2DM was conducted using database
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login